

To: (b)(7)(C) (10)(2e) (b)(7)(C) (10)(2e) @minvws.nl; (b)(7)(C) (10)(2e) (b)(7)(C) (10)(2e) @minvws.nl; (b)(7)(C) (10)(2e) (b)(7)(C) (10)(2e) @minvws.nl; (b)(7)(C) (10)(2e) (b)(7)(C) (10)(2e) @rijksoverheid.nl; (b)(7)(C) (10)(2e) (b)(7)(C) (10)(2e) @mckinsey.com; (b)(7)(C) (10)(2e) (b)(7)(C) (10)(2e) @mckinsey.com; (b)(7)(C) (10)(2e) (b)(7)(C) (10)(2e) @mckinsey.com]

From: Paul Rutten

Sent: Mon 9/21/2020 9:28:10 PM

Subject: RE: VWS/McKinsey: clarification part of the European Tendering process 'Study into the Ecosystem surrounding the development of medicines'

Received: Mon 9/21/2020 9:29:02 PM

[881679 On Pins and Needles - Will COVID-19 Vaccines Save the World.pdf](#)

[879600 COVID-19 Implications for Life Sciences R&D Recovery and the Next Normal.pdf](#)

Dear VWS-colleagues,

It was nice to meet you today in our session together and also great to hear your questions. We wanted to share with you (a limited set of) the references to articles we mentioned in the course of conversation. For example, we wanted to give you some flavor of the future of pharma R&D in reaction to your question why we thought it was interesting to add a question about the future of research.

Please do not hesitate to let us know if there are any remaining questions.

As stated, we wish you a lot of wisdom!

Kind regards,

(b)(7)(C) (10)(2e)

1. **COVID-19 implications for life sciences R&D: Recovery and the next normal;** <https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/our-insights/covid-19-implications-for-life-sciences-r-and-d-recovery-and-the-next-normal>; this explains impact on pharma R&D but also on the digital adoption to run trials which could impact trials costs
2. **Clinical trial recovery from COVID-19 disruption;** <https://www.nature.com/articles/d41573-020-00150-9>; this is the external publication also confirming R&D leaders expectation on adoption of new ways of doing development.
3. **Developing Covid-19 Vaccines at Pandemic Speed;** New England Journal of Medicine (DOI: 10.1056/NEJMp2005630); potential implications on new ways to think about R&D acceleration.
4. **On pins and needles: Will COVID-19 vaccines 'save the world'?** A summary on the latest information on research timelines and the potential impact of a vaccine on the pandemic and society

(b)(7)(C) (10)(2e)

Tel: +31 (0) (b)(7)(C) (10)(2e)

Email: (b)(7)(C) (10)(2e) @mckinsey.com

Assistant: (b)(7)(C) (10)(2e) Tel: +31 (0)20 (b)(7)(C) (10)(2e) E-mail: (b)(7)(C) (10)(2e) @mckinsey.com
McKinsey & Company, Amstel 344, 1017 AS Amsterdam, the Netherlands

-----+-----
This email is confidential and may be privileged. If you have received it in error, please notify us immediately and then delete it. Please do not copy it, disclose its contents or use it for any purpose.
-----+-----